Whenever possible, the Panel recommends that promising, unapproved, or unlicensed treatments for COVID-19 be studied in well-designed, controlled clinical trials. This recommendation also applies to drugs that have been approved or licensed for indications other than the treatment of COVID-19.
The Panel recognizes the critical importance of clinical research in generating evidence to address unanswered questions regarding the safety and efficacy of potential treatments for COVID-19.
However, the Panel also realizes that many patients and providers who cannot access these potential treatments via clinical trials still seek guidance about whether to use them.
A large volume of data and publications from randomized controlled trials, observational cohorts, and case series are emerging at a very rapid pace, some in peer-reviewed journals, others as manuscripts that have not yet been peer reviewed, and, in some cases, press releases. The Panel continuously reviews the available data and assesses their scientific rigor and validity. These sources of data and the clinical experiences of the Panel members are used to determine whether new recommendations or changes to the current recommendations are warranted.
Finally, it is important to stress that the rated treatment recommendations in these Guidelines should not be considered mandates. The choice of what to do or not to do for an individual patient is ultimately decided by the patient and their provider.
Go to the link below for full NIH article: https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/introduction/#:~:text=Finally%2C%20it%20is%20important%20to,the%20patient%20and%20their%20provider.
Thanks for doing the link. I am hamstrung with tech confusion.
That’s a Deep State obfuscation.
It’s decided by the provider’s employer.
If the prescriber’s employer, and most are employed by health systems now (thanks GWB), says no Ivermectin, unless said employee is courageous enough to risk his job and/or his license, guess what he’ll do.